Advertisement

International Journal of Hematology

, Volume 110, Issue 3, pp 306–312 | Cite as

Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens

  • Jorge Vela-OjedaEmail author
  • Miriam America García-Ruiz Esparza
  • Abraham Majluf-Cruz
  • Jaime García-Chavez
  • Laura Arcelia Montiel-Cervantes
  • Elba Reyes-Maldonado
  • Alvaro Hernandez-Caballero
  • Maria Guadalupe Rodríguez-González
Original Article

Abstract

Multiple myeloma (MM) is a disease characterized by antitumoral immune dysfunction. The objective of the present study was to determine lymphocyte subsets (B, T, NK, NKT, iNKT, dendritic cells, and regulatory T cells) in 68 newly diagnosed patients and 113 healthy donors. Lymphocyte subsets were studied in the same patients 6 months after treatment. Pre-treatment values of CD4+ T cells, NK cells, type 2 dendritic cells, and B cells in MM patients were lower than in healthy donors. Forty patients (59%) received MPT treatment and 28 (41%) thal–dex. Patients with no response to treatment, exhibited a decrease in CD4+ T cells and NK cells, as well as an increase in Treg cell numbers. Median DFS and OS was lower in patients not achieving response, in patients having low numbers of NK cells, and higher values of LDH. The number of CD4 T cells, NK, DC2, and B cells at diagnosis is lower in patients with MM. Non-responder patients had lower CD4 and NK, but higher Treg cell values. Patients in which response is not achieved, and those holding lower values of NK cells and higher levels of LDH, have poor DFS and OS.

Keywords

Myeloma NK cells Treg cells LDH Prognostic factors 

Notes

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336:1657–64.CrossRefPubMedGoogle Scholar
  2. 2.
    Schutt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Müller S, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma. 2006;47(8):1570–82.CrossRefPubMedGoogle Scholar
  3. 3.
    Nucci M, Anaisssie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49:1211–25.CrossRefPubMedGoogle Scholar
  4. 4.
    Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, Garcia-Laraña J, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3):529–34.CrossRefPubMedGoogle Scholar
  5. 5.
    Caligiuri MA. Human natural killer cells. Blood. 2008;112:461–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950–61.CrossRefPubMedGoogle Scholar
  7. 7.
    Ogmundsdottir HM. Natural killer cell activity in patients with multiple myeloma. Cancer Detect Prev. 1988;12:133–43.PubMedGoogle Scholar
  8. 8.
    Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol. 2005;86:209–39.CrossRefPubMedGoogle Scholar
  9. 9.
    Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005;128:192–203.CrossRefPubMedGoogle Scholar
  10. 10.
    Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73.CrossRefPubMedGoogle Scholar
  11. 11.
    San Miguel JF, Gonzalez M, Gascon A, Moro MJ, Hernandez JM, Ortega F, et al. Lymphoid subsets and prognostic factors in multiple myeloma. Br J Haematol. 1992;80(3):305–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98:579–85.CrossRefPubMedGoogle Scholar
  13. 13.
    Jurisic V, Srdic T, Konjevic G, Markovic O, Colovic M. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol. 2007;24:312–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105:251–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Bernal M, Garrido P, Jimenez P, Carretero R, Almagro M, Lopez P, et al. Changes in the activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum Immunol. 2009;70:854–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Konjević G, Vuletić A, Mirjačić Martinović K, Colović N, Čolović M, Jurišić V. Decreased CD161 activating and increased CD158a inhibitory receptor expression on NK cells underlies impaired NK cell cytotoxicity in patients with multiple myeloma. J Clin Pathol. 2016;69:1009–166.CrossRefGoogle Scholar
  17. 17.
    Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev. 1999;13:51–64.CrossRefPubMedGoogle Scholar
  18. 18.
    Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoi R, Oliviero B, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood. 2002;100:230–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16:309–23.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Feyler S, Selby PJ, Cook G. Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM). Blood Rev. 2013;27:155–64.CrossRefPubMedGoogle Scholar
  21. 21.
    Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006;107:301–4.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Pessoa de Magalhaes RJ, Vidriales MB, Paiva B, Fernandez-Gimenez C, Garcia-Sanz R, Mateos MV, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98(1):79–86.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58:1033–45.CrossRefPubMedGoogle Scholar
  25. 25.
    Wu L, Parton A, Lu L, Adams M, Schafer P, Barlett JB. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother. 2011;60(1):61–73.CrossRefPubMedGoogle Scholar
  26. 26.
    Barlogie B, Smallwood L, Smith T, Alexanian R. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med. 1989;110(7):521–5.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Jorge Vela-Ojeda
    • 1
    • 2
    • 4
    Email author
  • Miriam America García-Ruiz Esparza
    • 1
  • Abraham Majluf-Cruz
    • 3
  • Jaime García-Chavez
    • 1
    • 2
  • Laura Arcelia Montiel-Cervantes
    • 1
    • 2
    • 4
  • Elba Reyes-Maldonado
    • 4
  • Alvaro Hernandez-Caballero
    • 1
  • Maria Guadalupe Rodríguez-González
    • 1
  1. 1.Hematology DepartmentUMAE Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro SocialMexico CityMexico
  2. 2.Unidad de Investigación de Medicina Traslacional en Enfermedades Hemato-Oncologicas, UMAE Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro SocialMexico CityMexico
  3. 3.Unidad de Investigación Medica en Trombosis, Hemostasia y Aterogenesis Hospital Carlos Mc Gregor, Instituto Mexicano del Seguro SocialMexico CityMexico
  4. 4.Escuela Nacional de Ciencias Biologicas, Instituto Politecnico NacionalMexico CityMexico

Personalised recommendations